Tag: EU Policy

Two decades after the first Medicinal Products Regulation and Directive was adopted, the EU is re-opening a pandora’s box of legislation in response to long-standing concerns that the current European pharmaceutical framework does not go far enough to address unmet medical needs, inequities in access to approved therapies and the burden of rising costs on national health care budgets...

The EU has placed itself at the forefront of sustainability efforts, with ambitious climate laws and a 2050 deadline for carbon neutrality...

Decoding and navigating the EU system provides the time, opportunities and tools for stakeholders to raise, address and shape the decision-making processes...

The COVID-19 crisis has been an eye-opener for many stakeholders, especially national governments, and has revealed that sharing health data is essential for enabling positive health outcomes and more sustainable health systems in Europe...

Every seven years the EU is convulsed by negotiations over its budget—the Multi-annual Financial Framework (MFF). The narrative is familiar and repetitive: predictions of stalemate and catastrophic breakdown are at some stage transformed into grumpy acceptance of a new deal with sweeteners for everyone. The question is, when will that transformation happen?..

The COVID-19 crisis has given a boost to those who want the EU to play a bigger role in health. Only time will tell if EU Member States are really willing to take the jump and commit to a true “Europe of Health.”..

Earlier this week, on 28 May, the European Commission published its first proposal to review the European Union’s pharmaceutical innovation incentives...